Who
Anthony M. Manning
Director
Company insider
Files Form 4 as: Director, Monte Rosa Therapeutics; Director, Palatin Technologies; Chief Scientific Officer, Momenta Pharmaceuticals.
In numbers
- Trades disclosed
- 147
- Buys
- 0
- Sells
- 40
- Bought
- $0
- Sold
- $7.2M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 7 Sep 2017
- Last trade
- 29 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 30 Jun 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K10,000 at $4.16 | filing |
| 29 Jun 2026filed 30 Jun 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $231K10,000 at $23.11 | filing |
| 29 Jun 2026filed 30 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 29 Jun 2026filed 30 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 29 Jun 2026filed 30 Jun 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K10,000 at $4.16 | filing |
| 29 Jun 2026filed 30 Jun 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $231K10,000 at $23.11 | filing |
| 11 Jun 2026filed 12 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,800 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K10,000 at $4.16 | filing |
| 21 May 2026filed 22 May 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $180K10,000 at $18.01 | filing |
| 21 May 2026filed 22 May 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 21 May 2026filed 22 May 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Code M | $42K10,000 at $4.16 | filing |
| 21 May 2026filed 22 May 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $180K10,000 at $18.01 | filing |
| 13 Jun 2025filed 16 Jun 2025 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 15 Jul 2024filed 16 Jul 2024 | PTN Palatin TechnologiesBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 12 Jun 2024filed 13 Jun 2024 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,100 at $0.00 | filing |
| 25 Jul 2023filed 26 Jul 2023 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,000 at $0.00 | filing |
| 15 Jul 2023filed 16 Jul 2024 | PTN Palatin Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 20 Jun 2023filed 22 Jun 2023 | PTN Palatin Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)GLUE · tickerreport.com · 16 Oct 2026Monte Rosa Therapeutics (NASDAQ:GLUE) Upgraded to "Hold" at UBS GroupGLUE · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Anthony M. Manning; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.